[HTML][HTML] CK-3, a novel methsulfonyl pyridine derivative, suppresses hepatocellular carcinoma proliferation and invasion by blocking the PI3K/AKT/mTOR and MAPK …
Q Wu, T Liu, B Hu, X Li, Y Wu, X Sun, X Jiang… - Frontiers in …, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC) is an aggressive tumor with a poor prognosis that highly
expresses phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (ERK) …
expresses phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (ERK) …
Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
Q Zhou, VWY Lui, W Yeo - Future oncology, 2011 - Taylor & Francis
Despite recent advances in the understanding of the biologic basis of hepatocellular
carcinoma (HCC) development, the clinical management of the disease remains a major …
carcinoma (HCC) development, the clinical management of the disease remains a major …
DZW-310, a novel phosphoinositide 3-kinase inhibitor, attenuates the angiogenesis and growth of hepatocellular carcinoma cells via PI3K/AKT/mTOR axis
Y Wu, X Xu, M Liu, X Qin, Q Wu, H Ding… - Biochemical …, 2022 - Elsevier
Hepatocellular carcinoma (HCC) is one of the most malignant tumors worldwide with high
lethality and prevalence. The deregulated phosphoinositide 3-kinase/protein kinase …
lethality and prevalence. The deregulated phosphoinositide 3-kinase/protein kinase …
Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma
Y Chen, L Zhang, C Yang, J Han, C Wang… - Bioorganic & Medicinal …, 2016 - Elsevier
Abstract The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of
rapamycin (mTOR) signaling pathway is related to cellular activities. Abnormalities of this …
rapamycin (mTOR) signaling pathway is related to cellular activities. Abnormalities of this …
Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma
MN Kim, SM Lee, JS Kim, SG Hwang - Cancer chemotherapy and …, 2019 - Springer
Purpose Sorafenib has been the only first systemic drug that improves survival of patients
with advanced hepatocellular carcinoma (HCC). However, because the response rate of …
with advanced hepatocellular carcinoma (HCC). However, because the response rate of …
Single agent and synergistic activity of the “first-in-class” dual PI3K/BRD4 inhibitor SF1126 with sorafenib in hepatocellular carcinoma
AR Singh, S Joshi, AM Burgoyne, JK Sicklick… - Molecular cancer …, 2016 - AACR
Abstract Deregulated PI3K/AKT/mTOR, Ras/Raf/MAPK, and c-Myc signaling pathways are of
prognostic significance in hepatocellular carcinoma (HCC). Sorafenib, the only drug …
prognostic significance in hepatocellular carcinoma (HCC). Sorafenib, the only drug …
[HTML][HTML] BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway
X Liu, C Xie, A Li, Y Zhang, X Liu, S Zhou… - American Journal of …, 2019 - ncbi.nlm.nih.gov
Desensitization of hepatocellular carcinoma (HCC) to paclitaxel chemotherapy is a major
deterrent to successful treatment of the cancer. Abnormal activation of the PI3K/Akt/mTOR …
deterrent to successful treatment of the cancer. Abnormal activation of the PI3K/Akt/mTOR …
Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor
KH Jung, HM Zheng, Y Jeong, MJ Choi, H Lee… - Cancer letters, 2013 - Elsevier
Dysregulation of the phosphoinositide 3-kinase (PI3K)/AKT/mTOR signaling pathway
frequently instigates tumorigenesis leading to hepatocellular carcinoma (HCC). We …
frequently instigates tumorigenesis leading to hepatocellular carcinoma (HCC). We …
[HTML][HTML] DHW-208, A novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-hepatocellular carcinoma activity through promoting apoptosis and inhibiting …
S Wang, Y Wu, M Liu, Q Zhao, L Jian - Frontiers in Oncology, 2022 - frontiersin.org
Hepatocellular carcinoma (HCC) is one of the most common tumors worldwide with high
prevalence and lethality. Due to insidious onset and lack of early symptoms, most HCC …
prevalence and lethality. Due to insidious onset and lack of early symptoms, most HCC …
The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment
R Gedaly, P Angulo, C Chen, KT Creasy… - Anticancer …, 2012 - ar.iiarjournals.org
Background: Deregulated RAS/RAF/MAPK and PI3K/AKT/mTOR signaling pathways are
found in hepatocellular carcinoma (HCC). This study aimed to test the inhibitory effects of PI …
found in hepatocellular carcinoma (HCC). This study aimed to test the inhibitory effects of PI …